Hypervascularized bronchial arteries as a risk factor for intraoperative bleeding and prolonged surgery.

BACKGROUND: The present study investigated whether highly vascularized bronchial arteries affect the intraoperative blood loss and the operative time of video-assisted thoracic surgery (VATS) lobectomy for patients with non-small cell lung cancer.
Methods: We retrospectively collected data on consecutive pathological stage I to IIIA non-small cell lung cancer patients who underwent VATS lobectomy with systematic lymph node dissection between January 2017 and December 2019. Patients were divided into the following two groups according to bronchial artery diameters on preoperative enhanced contrast computed tomography (CT) findings: ≤2 and >2 mm groups.
RESULTS: Among the 175 patients enrolled, risk factors for intraoperative blood loss >50 mL were being male (P=0.005), a history of smoking (P=0.01), percent forced expiratory volume in 1 s (FEV1.0%) <70% (P=0.012), squamous cell carcinoma (P=0.049), and a bronchial artery diameter >2.0 mm (P<0.001) in the unadjusted analysis, and a bronchial artery diameter >2.0 mm (P<0.001) in the multivariable analysis. Risk factors for an operative time >200 min were being male (P<0.001), a history of smoking (P=0.007), FEV1.0% <70% (P=0.011), squamous cell carcinoma (P=0.046), a bronchial artery diameter >2.0 mm (P<0.001), and experience of surgeon <10 years (P=0.011) in the unadjusted analysis, and being male (P=0.047), a bronchial artery diameter >2.0 mm (P=0.024), and experience of surgeon <10 years (P=0.047) in the multivariable analysis.
CONCLUSIONS: Bronchial artery diameter was the most important risk factor of intraoperative bleeding and prolonged operative time during VATS lobectomy. 2021 Journal of Thoracic Disease. All rights reserved.

Introduction

The standard surgical procedure for primary lung cancer is lobectomy with systematic lymph node dissection, and video-assisted thoracic surgery (VATS) has recently become more mainstream (1). It has been nearly 30 years since VATS lobectomy was initially reported (2). In Japan, approximately 70% of surgeries performed for primary lung cancer involve VATS, and the 30-day postoperative mortality rate is 0.3%, which is very safe (3). In recent year, the feasibility of VATS lobectomy for stage II (cN1) non-small cell lung cancer (NSCLC) has also been demonstrated (4). Although the surgical procedure for VATS lobectomy is established and widely performed, increases in both intraoperative bleeding and the operative time are sometimes encountered.

The sequence of vessel interruption during lobectomy remains controversial (4-6). One of the merits of firstly sealing the pulmonary veins is that it may prevent the outflow of tumor cells into the circulation and distant metastasis (5). However, it may also cause congestion of the lobe to be resected, resulting in increases in both intraoperative blood loss and the operative time (6). However, previous studies reported no significant differences in intraoperative blood loss and operative times between cases in which either the pulmonary veins or arteries were initially sealed (5,7). One of the reasons for this finding is that not only pulmonary arteries, but also bronchial arteries may cause congestion of the lobe to be resected after pulmonary vein sealing.

Bronchial arteries generally originate from the proximal descending thoracic aorta (8,9). Normal bronchial arteries are small, measuring less than 2 mm at their origin, receive only approximately 1% of the total cardiac output, and help maintain airway and lung function (10,11). They provide a systemic blood supply to the trachea, bronchi, bronchial branches, esophagus, visceral pleura, vasa vasorum of the thoracic aorta, and pulmonary arteries as well as to the nerves, pulmonary veins, and lymph nodes in the thorax (12). Bronchial arteries carry oxygenated blood to the lungs at a pressure that is six-fold higher than that in the pulmonary arteries. Therefore, highly vascularized bronchial arteries may contribute to bleeding during lung cancer surgery.

The present study investigated whether highly vascularized bronchial arteries affect intraoperative blood loss in and the operative time of VATS lobectomy with systematic lymph node dissection, and attempted to identify the factors that correlate with hypervascularized bronchial arteries.

We present the following article in accordance with the STROBE reporting checklist (available at https://dx.doi.org/10.21037/jtd-21-616).

Methods

Patients

We retrospectively collected data on consecutive NSCLC patients who underwent resection at Tokushima University Hospital between January 2017 and December 2019. Patients who met the following criteria were included: pathologically confirmed stage I to IIIA NSCLC; no preoperative treatment; VATS lobectomy with systematic lymph node dissection; and complete curative resection. Patients with the following factors were excluded: no preoperative contrast-enhanced computed tomography (CT) or no arterial phase during contrast-enhanced CT, previous surgery on the ipsilateral thoracic cavity, the resection of surrounding tissue, simultaneous surgical procedures, and conversion from VATS to open surgery. The presence of interstitial lung disease was defined when CT findings showed ground-glass opacities, irregular linear opacities, honeycombing, or consolidation in the lung field. Clinicopathological, operative, and postoperative data were collected from a retrospective review of medical records. The Ethics Committee of Tokushima University Hospital approved the study protocol in March 2020 (No. 3672). The need for written informed consent was waived because of the retrospective study design. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013).

CT protocol

Contrast-enhanced CT images were acquired using a 16-slice multidetector CT (MDCT) scanner (Aquilion16; Toshiba Medical Systems Corporation, Tochigi, Japan; SOMATOM Sensation 16; Siemens, Erlangen, Germany) or a 320-slice MDCT scanner (Aquilion One; Toshiba Medical Systems Corporation, Tochigi, Japan). One hundred milliliters of iohexol (Omnipaque, 300 mg of iodine per milliliter; Daiichi-Sankyo Pharmaceutical, Tokyo, Japan) was intravenously injected at a rate of 3.0 mL/s, followed by an injection of 40 mL of saline solution. Arterial and equilibrium phase scanning was performed. In the arterial phase, scanning was initiated using a bolus-tracking method. The region of interest was set at the descending aorta, and the threshold for the CT value was 100 HU. When the CT value surpassed the threshold, scanning was automatically started and followed by equilibrium phase scanning 100 s after completion of the arterial phase. CT scanning was performed using the following parameters: gantry rotation speed of 0.5 s per rotation, 1-mm collimation for the 16-slice MDCT scanner and 0.5-mm collimation for the 320-slice MDCT scanner, 15 mm/s table increment with a helical pitch of 15, tube voltage of 120 kV, and tube current of 300 mA.

Measurement of the bronchial artery diameter

The identification and measurement of bronchial arteries were performed using commercially available software (Aquarius NET Viewer Version 4.4.11.265; TeraRecon Inc., San Mateo, CA, USA) (). In the arterial phase of contrast-enhanced CT, bronchial arteries leading to the lobe to be resected were identified. Artery diameters were measured at the point arising from the thoracic aorta (). On the right side, the artery was sometimes a common intercostal-bronchial artery trunk. Patients were divided into the following two groups based on bronchial artery diameters: ≤2 and >2 mm groups, since the diameter of the bronchial artery is usually 2 mm or less (10).

Figure 1

CT images of bronchial artery. (A) A three-dimensional CT image rendered using 1-mm-thick multi-detector CT images [arrowheads: an origin of the right bronchial artery (common intercostal-bronchial artery trunk)]; (B) a contrast-enhanced CT image in the arterial phase [arrowheads: an origin of the right bronchial artery (the common intercostal-bronchial artery trunk)]. CT, computed tomography.

Surgical procedures

Patients underwent VATS lobectomy with systematic hilar and mediastinal lymph node dissection. A 1.5-cm camera port was created in the 8th intercostal space at the midaxillary line, a 4-cm working window for the surgeon in the 4th intercostal space at the anterior axillary line, and a 3-cm working window for the assistant in the 6th or 7th intercostal space at the posterior axillary line. Endostaplers were used to seal the pulmonary artery, pulmonary vein, and bronchus and divide the interlobar fissure, and small branches of the vessels were sealed with LigaSure (Medtronic, Minneapolis, Minn). The sequence of procedures was decided by each surgeon. Mediastinal lymph node dissection was achieved after lobectomy in all cases. The TNM classification was assessed according to the Union for International Cancer Control staging system, version 8.

Statistical analysis

GraphPad prism 5 software was used to analyze the linear correlations between intraoperative blood loss, operative time, and bronchial artery diameter. The Mann-Whitney U test was used to calculate the impact of bronchial artery dilation on intraoperative blood loss and the operative time. The chi-squared test was performed to compare categorical variables. Pearson’s chi-squared test or Fisher’s exact test was applied to verify relationships between the groups. A logistic regression analysis was used to identify prognostic risk factors. Potentially predictive variables were identified using a significance level of P<0.10 by a univariate analysis and were then subjected to a logistic regression multivariable analysis. All statistical analyses were performed using IBM SPSS Statistics (version 22; IBM Corp., Armonk, NY, USA). P<0.05 was considered to be significant.

Results

Clinicopathological characteristics of NSCLC patients who underwent VATS lobectomy

A total of 215 patients underwent curative VATS lobectomy with systematic lymph node dissection for the treatment of pathological stage I to IIIA NSCLC without preoperative treatment during the study period. Among them, 40 patients were excluded because of no preoperative contrast-enhanced CT or no arterial phase during contrast-enhanced CT (n=34), lobectomy with chest wall resection (n=3), sleeve lobectomy (n=2), and simultaneous esophagectomy (n=1). There was no conversion case from VATS to open surgery. Therefore, 175 patients were included in the present study (); 109 males (62.3%) with a median age of 72 years [interquartile range (IQR), 66–78 years] and 106 with a history of smoking (60.6%). The median tumor size was 19 mm (IQR, 12–29 mm). Tumor locations were as follows: the right upper lobe in 66 patients (37.7%), the right middle lobe in 12 (6.9%), the right lower lobe in 34 (19.4%), the left upper lobe in 27 (15.4%), and the left lower lobe in 36 (20.6%). Interstitial lung disease was identified in 51 patients (29.1%). The histological type was squamous cell carcinoma in 33 patients (18.9%), adenocarcinoma in 128 (73.1%), and other types in 14 (8.0%). The pathological stages of 0/IA/IB/IIA/IIB/IIIA were 4 (2.3%)/127 (72.6%)/16 (9.1%)/6 (3.4%)/17 (9.7%)/5 (2.9%). The median diameter of bronchial arteries was 1.8 mm (IQR, 1.6–2.2 mm).

Figure 2

Flow chart for the study population. VATS, video-assisted thoracic surgery; LND, lymph node dissection; NSCLC, non-small cell lung cancer; CT, computed tomography.

Surgeons and outcomes of surgery

During the study period, 17 surgeons participated as the chief surgeon. Their years of experience as surgeons were 2, 3, 3, 4, 6, 7, 9, 10, 10, 12, 12, 12, 15, 20, 22, 22, and 22 years. In surgery performed by a surgeon with less than 15 years of experience, a senior doctor (experience of 20, 22, 22, 22, and 34 years) instructed the surgery as an assistant. Median intraoperative blood loss was 27 mL (IQR, 3–100 mL) and the median operative time was 197 min (IQR, 156–240 min). No patient required a blood transfusion due to intraoperative bleeding, reoperation and interventional radiology due to postoperative bleeding. No patient died during the perioperative period.

Correlations between intraoperative blood loss, operative time and bronchial artery diameter

shows correlation between intraoperative blood loss and bronchial artery diameter (r2=0.155, P<0.0001), and shows correlation between operative time and bronchial artery diameter (r2=0.105, P<0.0001). There were poor correlations between intraoperative blood loss, operative time and bronchial artery diameter.

Figure 3

Correlations between intraoperative blood loss, operative time and bronchial artery. (A) Correlations between intraoperative blood loss and bronchial artery diameter; (B) correlations between operative time and bronchial artery diameter.

Risk factors for intraoperative bleeding and prolongation of the operative time

shows intraoperative blood loss and operative times in the groups with bronchial artery diameters ≤2.0 and >2.0 mm. Risk factors for intraoperative blood loss >50 mL were being male (P=0.005), a history of smoking (P=0.01), percent forced expiratory volume in 1 s (FEV1.0%) <70% (P=0.012), squamous cell carcinoma (P=0.049), and a bronchial artery diameter >2.0 mm (P<0.001) in the unadjusted analysis (), and a bronchial artery diameter >2.0 mm (P<0.001) in the multivariable analysis (). Unadjusted analysis of intraoperative blood loss was also performed between ≤200 and >200 mL groups; however, the results were similar (). Risk factors for an operative time >200 min were being male (P<0.001), a history of smoking (P=0.007), FEV1.0% <70% (P=0.011), squamous cell carcinoma (P=0.046), a bronchial artery diameter >2.0 mm (P<0.001), and experience of surgeon <10 years (P=0.011) in the unadjusted analysis (), and being male (P=0.047), a bronchial artery diameter >2.0 mm (P=0.024), and experience of surgeon <10 years (P=0.047) in the multivariable analysis ().

Table 1

Clinicopathological characteristics

Variables	Intraoperative blood loss							Intraoperative blood loss							Operative time
	≤50 mL (n=100)			>50 mL (n=75)		P value		≤200 mL (n=150)			>200 mL (n=25)		P value		≤200 min (n=96)			>200 min (n=79)		P value
	N	%		N	%			N	%		N	%			N	%		N	%
Age						0.44							0.61							0.43
<70 years	39	60.9		25	39.1			56	87.5		8	12.5			38	59.4		26	40.6
≥70 years	61	55.0		50	45.0			94	84.7		17	15.3			58	52.3		53	47.7
Sex						0.005							0.013							<0.001
Male	54	49.1		56	50.9			89	80.9		21	19.1			49	44.5		61	55.5
Female	46	70.8		19	29.2			61	93.8		4	6.2			47	72.3		18	27.7
A history of smoking						0.01							0.028							0.007
No	47	69.1		21	30.9			63	92.6		5	7.4			46	67.6		22	32.4
Yes	53	49.5		54	50.5			87	81.3		20	18.7			50	46.7		57	53.3
FEV1.0%						0.012							0.021							0.011
<70%	31	44.9		38	55.1			54	78.3		15	21.7			30	43.5		39	56.5
≥70%	69	65.1		37	34.9			96	90.6		10	9.4			66	62.3		40	37.7
Tumor size						0.66							0.62							0.17
≤20 mm	54	58.7		38	41.3			80	87.0		12	13.0			55	59.8		37	40.2
>20 mm	46	55.4		37	44.6			70	84.3		13	15.7			41	49.4		42	50.6
Tumor location						0.97							0.73							0.62
Right upper	37	57.8		27	42.2			53	82.8		11	17.2			35	54.7		29	45.3
Right middle	7	58.3		5	41.7			11	91.7		1	8.3			4	33.3		8	66.7
Right lower	19	52.8		17	47.2			31	86.1		5	13.9			20	55.6		16	44.4
Left upper	15	55.6		12	44.4			23	82.1		5	17.9			16	59.3		11	40.7
Left lower	22	61.1		14	38.9			32	91.4		3	8.6			21	58.3		15	41.7
Interstitial lung disease						0.18							0.066							0.24
Absent	75	60.5		49	39.5			110	88.7		14	11.3			72	58.1		52	41.9
Present	25	49.0		26	51.0			40	78.4		11	21.6			24	47.1		27	52.9
Histological type						0.049							0.057							0.046
Squamous cell carcinoma	13	39.4		20	60.6			24	72.7		9	27.3			12	36.4		21	63.6
Adenocarcinoma	80	62.5		48	37.5			114	89.1		14	10.9			77	60.2		51	39.8
Others	7	50.0		7	50.0			12	85.7		2	14.3			7	50.0		7	50.0
Pathological stage						0.36							0.91							0.89
0	3	75.0		1	25.0			3	75.0		1	25.0			2	50.0		2	50.0
I	85	59.4		58	40.6			123	86.0		20	14.0			80	55.9		63	44.1
II	10	43.5		13	56.5			20	87.0		3	13.0			12	52.2		11	47.8
III	2	40.0		3	60.0			4	80.0		1	20.0			2	40.0		3	60.0
Bronchial artery diameter						<0.001							<0.001							<0.001
≤2.0 mm	84	68.3		39	31.7			114	92.7		9	7.3			78	63.4		45	36.6
>2.0 mm	16	30.8		36	69.2			36	69.2		16	30.8			18	34.6		34	65.4
Experience of surgeon						0.28							0.344							0.011
<10 years	36	52.2		33	47.7			57	82.6		12	17.4			30	43.5		39	56.5
≥10 years	64	60.4		42	39.6			93	87.7		13	12.3			66	62.3		40	37.7

Table 2

Multivariate analysis of relations with intraoperative blood loss and operative time

Variables	Intraoperative blood loss >50 mL				Operative time >200 min
	Risk ratio	95% confidence interval	P value		Risk ratio	95% confidence interval	P value
Sex (male vs. female)	1.533	0.601–3.907	0.371		2.603	1.013–6.686	0.047
A history of smoking (yes vs. no)	1.123	0.437–2.885	0.809		1.178	0.455–3.049	0.736
Histological type (squamous cell carcinoma vs. others)	1.209	0.493–2.967	0.678		1.335	0.546–3.257	0.526
Bronchial artery diameter (>2.0 vs. ≤2.0 mm)	3.921	1.859–83.333	<0.001		2.353	1.117–4.950	0.024
Experience of surgeon (<10 vs. ≥10 years)	–	–	–		1.946	1.010–3.745	0.047

Factors correlating with bronchial artery dilation

The bronchial artery diameter >2.0 mm group included more males (P<0.001), a history of smoking (P<0.001), the presence of interstitial lung disease (P<0.001), squamous cell carcinoma (P=0.049), and an advanced pathological stage ().

Table 3

Factors correlating with bronchial artery dilation

Variables	Bronchial artery diameter					P value
	≤2.0 mm (n=123)			>2.0 mm (n=52)
	N	%		N	%
Age						0.73
<70 years	46	71.9		18	28.1
≥70 years	77	69.4		34	30.6
Sex						<0.001
Male	65	59.1		45	40.9
Female	58	89.2		7	20.8
A history of smoking						<0.001
No	60	88.2		8	11.8
Yes	63	58.9		44	41.1
Tumor size						0.66
≤20 mm	75	81.5		17	18.5
>20 mm	48	57.8		35	42.2
Tumor location						0.06
Right upper	38	59.4		26	40.6
Right middle	11	91.7		1	8.3
Right lower	24	66.7		12	33.3
Left upper	22	81.5		5	18.5
Left lower	28	77.8		8	22.2
Interstitial lung disease						<0.001
Absent	100	80.6		24	19.4
Present	23	45.1		28	54.9
Histological type						0.049
Squamous cell carcinoma	13	39.4		20	60.6
Adenocarcinoma	106	82.8		22	17.2
Others	4	28.6		10	71.4
Pathological stage						0.004
0	4	100.0		0	0.0
I	107	74.8		36	25.2
II	10	43.5		13	56.5
III	2	40.0		3	60.0

Operative and postoperative results correlating with bronchial artery dilation

shows operative and postoperative results in the groups with bronchial artery diameters ≤2.0 and >2.0 mm. In the bronchial artery dilation group, intraoperative blood loss was significantly greater (median, 100 vs. 10 mL; IQR, 29–205 vs. 3–50 mL; P<0.0001), the operative time was significantly longer (median, 220 vs. 181 min; IQR, 196–314 vs. 151–219 min; P<0.0001), postoperative complications were significantly more frequent (38.5% vs. 9.8%; P<0.0001), and postoperative hospital stay significantly longer (median, 9 vs. 7 min; IQR, 8–13 vs. 6–9 min; P<0.0001).

Table 4

Operative and postoperative results correlating with bronchial artery dilation

Variables	Bronchial artery diameter		P value
	≤2.0 mm (n=123)	>2.0 mm (n=52)
Intraoperative blood loss (mL), median [IQR]	10 [3–50]	100 [29–205]	<0.0001
Operative time (min), median [IQR]	181 [151–219]	220 [196–314]	<0.0001
Postoperative complication, n (%)
Overall incidence	12 (9.8)	20 (38.5)	<0.0001
Air leakage over 7 days	1 (0.8)	6 (11.5)
Pneumonia	3 (2.4)	5 (9.6)
Chylothorax	0 (0.0)	1 (1.9)
Atelectasis	1 (0.8)	3 (5.8)
Recurrent nerve palsy	2 (1.6)	0 (0.0)
Acute myocardial infarction	0 (0.0)	1 (1.9)
Acute exacerbation of interstitial pneumonia	0 (0.0)	1 (1.9)
Atrial fibrillation	2 (1.6)	1 (1.9)
Postoperative bleeding	1 (0.8)	0 (0.0)
Home oxygen therapy	1 (0.8)	1 (1.9)
Wound infection	1 (0.8)	1 (1.9)
Postoperative hospital stay (days), median [IQR]	7 [6–9]	9 [8–13]	<0.0001
Death within 30 days postoperatively, n (%)	0 (0.0)	1 (1.9)	0.3

IQR, interquartile range.

Discussion

With advances in surgical techniques and devices, VATS has become a standard surgical procedure for lung cancer surgery (1). However, even thoracic surgeons with experience sometimes encounter unexpected intraoperative bleeding during VATS and, thus, the prolongation of operative times. The causes and incidence of intraoperative bleeding under 7 conditions are summarized by the International Interest Group on Bleeding during VATS Lung Surgery; bleeding from massive vessel injuries, bronchial arteries, vessel and bronchial stumps, lung parenchyma, lymph nodes, incisions, and the chest wall (13).

We herein focused on bronchial arteries because they supply blood to most intrathoracic tissues that may be incised or damaged during lobectomy and lymph node dissection. They provide a systemic blood supply to the trachea, bronchi, bronchial branches, esophagus, visceral pleura, vasa vasorum of the thoracic aorta, and pulmonary arteries as well as to the nerves, pulmonary veins, and lymph nodes in the thorax (12). In the present study, a bronchial artery diameter >2.0 mm was the only risk factor for intraoperative bleeding in the multivariate analysis, even though many surgeons with different years of experience were involved in surgery. This is the first study to show that hypervascularized bronchial arteries significantly increased both intraoperative blood loss and the operative time.

Factors related to a bronchial artery diameter >2.0 mm were being male, a history of smoking, the presence of interstitial lung disease, squamous cell carcinoma, and an advanced pathological stage. Bronchial arteries play an important role in diseases that affect the airways and lung parenchyma. One of the causes of bronchial artery dilatation is chronic or acute inflammation. The most common inflammatory lung and airway disorders associated with bronchial artery dilatation include tuberculosis and nontuberculous mycobacterial infections as well as chronic fungal infections (10,14,15). Although a history of these infections was not examined in the present study, they may cause intrathoracic adhesions and lymph node swelling, resulting in increases in intraoperative bleeding and operative times. Chronic inflammatory changes caused by smoking or interstitial lung disease may also lead to bronchial artery dilatation. Lung cancer (frequently necrotic squamous cell cancer) is also a cause of bronchial artery dilatation (10,16,17).

Intraoperative bleeding in cases with hypervascularized bronchial arteries has been observed during the following: (I) dissection of inflammatory intrathoracic adhesions; (II) dissection around hilar lymph nodes; (III) bleeding from the hilum or lung parenchyma due to lung congestion, and (IV) mediastinal lymph node dissection. Regarding bleeding from the hilum or lung parenchyma due to lung congestion, Li et al. previously reported that intraoperative blood loss was significantly less in the pulmonary vein sealing first group than in the pulmonary artery sealing first group (6). On the other hand, comparative studies by Sumitomo et al. (5) and Yellin et al. (7) did not show any significant differences in intraoperative blood loss between the two groups. Therefore, these findings and the present results suggest that intraoperative blood loss is affected by blood flow in the bronchial arteries rather than the sequence of vessel interruption.

Since patients with thick bronchial arteries are at risk of intraoperative bleeding during VATS lobectomy, risk management is required during surgery for these cases. Senior surgeons need to be aware that it may be difficult for an inexperienced resident to complete VATS lobectomy on a patient with highly vascularized bronchial arteries that are detected by preoperative contrast-enhanced CT. The International Interest Group on Bleeding during VATS Lung Surgery states in their recommendations that the pre-emptive clipping of bronchial arteries before bronchial dissection or lymph node dissection may reduce the incidence of bleeding (13). Since bronchial arteries markedly vary in terms of origin, the parent artery, and course through the mediastinum (8,9), they need to be carefully identified during surgery. Intraoperative observations using the indocyanine green fluorescent endoscopy system may facilitate the identification of bronchial arteries that run through the mediastinum and hilar and sealing before hilar dissection or lymph node dissection (18). The blockade of bronchial arteries first may reduce intraoperative bleeding and shorten the operative time. Further studies are warranted.

There are some limitations that need to be addressed. This was a retrospective study with a limited number of single-center cases. Furthermore, bronchial artery diameters were measured at the point arising from thoracic aorta. Right bronchial arteries often share their origin with an intercostal artery, a finding known as a common intercostal-bronchial artery trunk (8,9). Therefore, bronchial artery diameters may have been evaluated as being larger in cases with a tumor on the right side. Moreover, the present study did not consider ectopic arterial origins. Ectopic sites of origin include the subclavian artery, brachiocephalic trunk, thyrocervical trunk, internal mammary artery, and even a coronary artery (9,19,20).

Conclusions

In cases with highly vascularized bronchial arteries, intraoperative bleeding increases during VATS lobectomy with systematic lymph node dissection, the operative time is prolonged, and postoperative complications increases. A bronchial artery diameter >2.0 mm was identified as the independent risk factor for intraoperative bleeding in the multivariate analysis. Factors related to a bronchial artery diameter >2.0 mm were being male, a history of smoking, the presence of interstitial lung disease, squamous cell carcinoma, and an advanced pathological stage.

The article’s supplementary files as